Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.580
+0.210 (15.33%)
At close: May 23, 2025, 4:00 PM
1.560
-0.020 (-1.27%)
After-hours: May 23, 2025, 7:55 PM EDT
Company Description
Tiziana Life Sciences Ltd, a biotechnology company, specializes in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Ivor Elrifi |
Contact Details
Address: 14/15 Conduit Street London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer and Executive Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Founder and Executive Chairman |
| Keeren Shah | Chief Operating Officer and Chief Financial Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |
| May 9, 2025 | 6-K | Report of foreign issuer |
| May 8, 2025 | 20-F/A | Filing |
| May 6, 2025 | 20-F | Annual and transition report of foreign private issuers |
| May 6, 2025 | 6-K | Report of foreign issuer |
| Apr 30, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 23, 2025 | 6-K | Report of foreign issuer |
| Apr 2, 2025 | 6-K | Report of foreign issuer |